Dolor de cabeza (general)

DHA is co-administered with EPA in fish oil RCTs for Raynaud's. Combined EPA (3.96 g) plus DHA (2.64 g) daily for 17 weeks significantly reduced cold-induced vasospastic reactions in primary Raynaud's. DHA contributes antiplatelet and anti-inflammatory effects complementary to EPA. Life Extension's Raynaud's protocol and authoritative reviews list EPA and DHA together as supported interventions for primary Raynaud's.

A 17-week double-blind, placebo-controlled RCT in 35 Raynaud's patients found fish oil providing 3.96 g EPA daily significantly reduced cold-induced vasospastic reactions in primary Raynaud's but not secondary Raynaud's. A 12-week fish oil study confirmed delayed symptom onset on cold challenge versus placebo. EPA's antiplatelet and vasodilatory prostaglandin-modulating properties underlie the proposed benefit. EBSCO, PeaceHealth, and Scleroderma & Raynaud's UK cite EPA-containing fish oil as a supported natural intervention.

A double-blind placebo-controlled trial (Belch et al., 1985, PMID 4082084) of 12 capsules/day for 8 weeks showed evening primrose oil significantly reduced Raynaud's attack frequency and improved severity scores versus placebo. Its active component GLA stimulates PGE1 production. EBSCO Research Starters, Scleroderma & Raynaud's UK, and Adam/SBRMC cite EPO as a supported complementary option for primary and secondary Raynaud's.

A peer-reviewed food science review (Wright et al., J Food Sci 2005) identified garlic among select dietary components with documented studies showing ability to promote hand skin blood flow in Raynaud's phenomenon. Garlic's antiplatelet and vasodilatory constituents (allicin, ajoene) reduce platelet aggregation and vascular resistance. Integrative sources including Scleroderma & Raynaud's UK and institutional databases cite garlic as potentially beneficial for Raynaud's circulation.

A double-blind, placebo-controlled RCT (Muir et al., Vasc Med 2002, PMID 12710841) found standardized ginkgo biloba extract at 360 mg/day for 10 weeks reduced Raynaud's attacks per week by 56% versus 27% for placebo in primary Raynaud's patients. Ginkgo's platelet-activating factor antagonism and vasodilatory mechanisms are proposed to attenuate episodic digital vasospasm. A Korean comparative RCT (KOARA study) also evaluated ginkgo against nifedipine for primary Raynaud's. It is the best-researched herbal remedy for Raynaud's according to Scleroderma & Raynaud's UK.

Korean red ginseng (Panax ginseng) was studied in a randomized double-blind placebo-controlled trial (Park et al., J Ethnopharmacol 2014, PMID 25284751) for cold hypersensitivity in the hands and feet — a condition overlapping with Raynaud's — and demonstrated significantly increased skin temperature, reduced discomfort, and improved response to cold exposure versus placebo. ConsumerLab and the Raynaud's Association cite this as evidence relevant to Raynaud's phenomenon. Traditional Korean medicine also uses ginseng for cold extremities and poor peripheral circulation.

Ginsenosides are the primary bioactive constituents of Korean red ginseng responsible for its vasodilatory and peripheral circulation-improving effects relevant to Raynaud's. The RCT (Park et al., J Ethnopharmacol 2014) demonstrating improved hand/foot skin temperature and cold tolerance in a condition overlapping with Raynaud's is attributed mechanistically to ginsenosides' vasodilatory action. They are not studied in isolation for Raynaud's but are the active fraction of ginseng with documented peripheral vascular effects.

GLA, an omega-6 fatty acid found in evening primrose oil, was studied in a double-blind placebo-controlled trial (Belch et al., 1985, PMID 4082084) where 12 capsules/day of evening primrose oil for 8 weeks resulted in significantly fewer Raynaud's attacks and improved severity scores versus placebo. GLA stimulates endogenous PGE1 production, promoting vasodilation and inhibiting platelet aggregation. Peer-reviewed reviews and Scleroderma & Raynaud's UK cite GLA (~320 mg/day) as one of few dietary components with documented evidence for Raynaud's.

As inositol hexanicotinate (inositol hexaniacinate), an 84-day double-blind placebo-controlled trial (n=23, primary Raynaud's; Sunderland, Clin Rheumatol 1988) found significantly reduced attack frequency and duration during cold weather versus placebo. Earlier thermographic controlled studies (Holti 1979; Ring 1977) confirmed improved digital blood flow. Multiple institutional sources including EBSCO Research Starters, PeaceHealth, and Adam/SBRMC list inositol hexanicotinate as a supported intervention for primary Raynaud's.

IHN (marketed as Hexopal) is the most evidence-supported use of inositol nicotinate, with multiple RCTs demonstrating reduced frequency and duration of vasospastic attacks in Raynaud's disease. A 1988 double-blind RCT (Sunderland et al., Clin Rheumatol) in 23 primary Raynaud's patients found that 4 g/day Hexopal produced shorter and fewer attacks. Thermographic studies also confirmed improvements in digital microcirculation. The mechanism involves vasodilation and possible enhanced fibrinolysis.

L-arginine is the precursor to nitric oxide (NO), a vasodilator, and has been studied in Raynaud's phenomenon. A small case report found oral L-arginine reversed digital necrosis in Raynaud's. However, a double-blind crossover trial of 8 g/day failed to show benefit for primary Raynaud's, and a 2009 meta-analysis (Malenfant) included L-arginine among RCT subcategories for Raynaud's CAM. Examine.com notes L-arginine did not demonstrate benefits in enhancing blood flow for Raynaud's.

A peer-reviewed food science review (Wright et al., J Food Sci 2005) identified L-carnitine among the select dietary components with documented studies showing ability to promote hand skin blood flow and increase hand skin temperature in Raynaud's phenomenon, alongside fish oil, garlic, ginkgo biloba, and inositol nicotinate. L-carnitine's vasoactive and endothelial-supportive properties provide a mechanistic rationale. No dedicated large RCT for L-carnitine alone in Raynaud's has been published.

Omega-3 fatty acids (EPA and DHA from fish oil) were studied in a 17-week double-blind placebo-controlled RCT in 35 Raynaud's patients and significantly reduced cold-induced vasospastic reactions in primary Raynaud's. A 2009 CAM meta-analysis (Malenfant, Rheumatology) included three essential fatty acid RCTs for Raynaud's. Scleroderma & Raynaud's UK and multiple institutional sources recommend increasing omega-3 oil consumption for Raynaud's management.

A clinical study published in Minerva Cardioangiologica (2019) demonstrated Pycnogenol improves microcirculation and reduces main symptoms of mild, primary Raynaud syndrome. The improvement in peripheral vascular function aligns with Pycnogenol's established mechanisms of endothelial nitric oxide enhancement and platelet aggregation inhibition.

A pilot trial comparing Pycnogenol plus standard therapy versus standard therapy alone in women with primary Raynaud's found significant improvements in blood flow, tissue oxygen levels, symptom scores (coldness, burning pain, paresthesia, color changes), and reduced oxidative stress biomarkers. A non-blinded preliminary study (Hu, Minerva Cardioangiol 2019) also showed reduced pain, discoloration, and increased finger temperature. ConsumerLab and Examine.com confirm Pycnogenol among supplements with demonstrated blood flow improvements for Raynaud's.

Niacin (vitamin B3), particularly as inositol hexanicotinate, has controlled trial evidence reducing Raynaud's attack frequency and duration. An 84-day DBPC trial (n=23, primary Raynaud's) found inositol hexanicotinate significantly reduced attacks versus placebo. Alpha-tocopherol nicotinate (600 mg/day, 6 weeks) improved numbness and cold sensation in vibration-induced Raynaud's. Institutional sources including Life Extension, PeaceHealth, and Adam/SBRMC cite niacin forms as supported interventions for primary Raynaud's.

Niacinamide (nicotinamide) is a form of vitamin B3 with peripheral vasodilatory properties sharing mechanistic overlap with niacin and inositol hexanicotinate, which have controlled trial evidence for reducing Raynaud's attack frequency. Inositol hexanicotinate significantly reduced attack frequency and duration in an 84-day DBPC trial (n=23, primary Raynaud's). Institutional sources including Life Extension, PeaceHealth, and EBSCO list B3 forms as supported natural interventions for Raynaud's.

Raynaud's patients have been found to have significantly lower plasma vitamin C levels versus healthy controls. Vitamin C (500 mg/day for 30 days) has been shown to promote vasodilation and improve blood flow in vascular disease sharing risk factors with secondary Raynaud's. Scleroderma & Raynaud's UK recommends vitamin C as an antioxidant that may protect blood vessels in Raynaud's, and it is included in CAM antioxidant trials reviewed in the 2009 Malenfant meta-analysis.

Alpha-tocopherol nicotinate (600 mg/day for 6 weeks) improved subjective symptoms including numbness and cold sensation in patients with vibration-induced Raynaud's in a published clinical study. Scleroderma & Raynaud's UK recommends vitamin E as an antioxidant that may protect blood vessels in Raynaud's. The 2009 Malenfant meta-analysis included antioxidant trials (including vitamin E) among CAM RCTs for Raynaud's.

Magnesium is cited by multiple institutional sources including Adam/SBRMC and integrative medicine databases as a supplement that opens blood vessels and may relax constricted blood vessels in Raynaud's. However, Adam/SBRMC explicitly notes there are no controlled scientific studies demonstrating its efficacy specifically for Raynaud's. It is recommended by some clinicians based on known cardiovascular vasodilatory properties. Scleroderma & Raynaud's UK lists it among supplements used for circulatory problems in Raynaud's.

Raynaud's syndrome is among the most specific traditional indications for prickly ash berries, documented in multiple herbal monographs and referenced in mainstream sources including RxList. It is used on the basis of the herb's classification as a peripheral circulatory stimulant that improves blood flow to the extremities. No clinical trials in humans support this use.